Publish time: 2023-11-06 00:00:00
12A-1100709
PCT and TW application pending
Schizophrenia is a severe mental disorder characterized by a range of thought- and behavior-related symptoms. Hyperactive dopaminergic signal transduction is believed to contribute to symptoms of schizophrenia. To date, antipsychotics that modulate dopamine neurotransmission remain to be the major treatment for schizophrenia, especially positive symptoms. Nonetheless, these dopaminergic antipsychotics usually have significant side effects and approximately 1/3 of patients do not respond well. We evaluated a novel compound which is an oral active adenosine analogue that simultaneously modulates and adenosine transporter (ENT1) and A2A adenosine receptor in a mouse model of schizophrenia . Treatment with the novel compound lowered methamphetamine-induced hyperlocomotion compared to controls.
- Approximately one third of patients with schizophrenia do not respond to dopaminergic antipsychotics
- The novel compound is an orally active adenosine analogue that can pass the blood-brain-barrier.
- The novel compound modulates adenosine transporter and A2A receptors, which indirectly regulate dopamine receptors.
Drug for schizophrenia
Yijuang Chern, Wen-Sung Lai, and Jim-Min Fang
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

A compound for the treatment of schizophrenia